Co-Diagnostics reports Q2 revenue of $27.4M, EPS $0.33; guides Q3 revenue $23-25M

Co-Diagnostics, Inc.

2021-Q2 EPS reported $0.59 revenue$47,382,909

Revenue $27.4M (+13.8% YoY); net income $9.8M ($0.33 diluted EPS) vs $15.0M ($0.51) in Q2 2020.
Gross profit margin 90.8% ($24.9M); operating income $11.8M (-19.8% YoY) due to higher R&D and sales commissions.
Cash and marketable securities $72.4M as of June 30; operating cash flow YTD $24.7M.
Q3 guidance: revenue $23-25M, diluted EPS $0.19-$0.22, effective tax rate ~19%, shares ~30M.
Over 20M tests sold to-date; CE-mark for Logix Smart Direct Saliva test; new international CoPrimer patent.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.